Search

News Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia

Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with schizophrenia and schizoaffective disorders perceive antipsychotic treatment, a larger survey was conducted in the USA in 2016.

Source: Modern Treatment of Schizophrenia 9. 10. 2023

News Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM

Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy of symptomatic treatment with mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), with the longest follow-up period nearly 2.5 years. For clinical practice, the long-term reduction of left ventricular outflow tract (LVOT) obstruction and good tolerability of the treatment are particularly favorable.

Source: Hypertrophic Cardiomyopathy (HCM) 19. 2. 2024

News L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section

The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and Nutrition focused on comparing the effect of infant formula containing Lactobacillus reuteri DSM 17938 on the microbiota of children born by cesarean section or vaginal delivery.

Source: GI, colic and microbiome 15. 5. 2020

News Current ASH Guidelines on ITP Management 2019 –⁠ Recommendations for Newly Diagnosed ITP in Children

At the end of 2019, the American Society of Hematology (ASH) published current guidelines for immune thrombocytopenia (ITP), in which a panel of experts attempted to define evidence-based recommendations for the care management of these patients.

Source: Immune Thrombocytopenia 22. 4. 2020

News Efficacy and Safety of Ultrahypofractionated Proton Therapy in the Treatment of Prostate Cancer in Real-World Czech Practice

A team from the Prague Proton Therapy Center, led by Associate Professor Jiří Kubeš, published a study with nearly 300 patients in the prestigious International Journal of Radiation Oncology, Biology, Physics. It demonstrates the significant efficacy and low toxicity of the ultrahypofractionated proton therapy regimen in patients with prostate cancer. We summarize the main results.

Source: Proton Radiotherapy 5. 4. 2023

News Does Peritoneal Dialysis Have Its Place Even in Acute Cases?

In patients who urgently need to replace kidney function, hemodialysis traditionally played the role of the gold standard. Can peritoneal dialysis fully replace it?

Source: Chronic Kidney Disease 8. 6. 2021

News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment

The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.

Source: Oncological Treatment 15. 10. 2021

News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis

What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC). .

Source: Amyloidosis 27. 2. 2023

News The Immune System in the Pathophysiology of ITP

From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.

Source: Immune Thrombocytopenia 9. 4. 2022

News After 20 years, a new treatment option for primary biliary cholangitis arrives

Primary biliary cholangitis (PBC), formerly known as cirrhosis, is a rare disease with a negative impact on prognosis and quality of life. While ursodeoxycholic acid (UDCA) has been essentially the only treatment option for PBC so far, in 2016, the European Medicines Agency (EMA) approved obeticholic acid as a second-line option. Since 2019, this medication has been available and fully covered by health insurance in 11 selected centers in the Czech Republic.

Source: Primary Biliary Cholangitis 10. 6. 2020

News Diabetic Cardiovascular Autonomic Neuropathy: How to Detect This Serious Diagnosis and Why Is It Dangerous?

Diabetic autonomic neuropathy can affect various organ systems. Cardiovascular autonomic neuropathy is one of its most severe forms with a significant impact on patient morbidity and mortality. How can it be detected in clinical practice?

Source: Diabetes 27. 1. 2022

News Expanded Vaccination Option Against Pneumococci Thanks to 15valent Vaccine

Our arsenal for preventing pneumococcal diseases has been expanded with a 15-valent conjugate vaccine that includes important serotypes causing invasive pneumococcal diseases (IPD). The following text briefly summarizes basic information not only about IPD, their prevention, diagnosis, and treatment, but especially about the management of vaccination with the 15-valent vaccine in practice.

Source: Regular Vaccination 20. 6. 2023

News Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?

How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous hematopoietic stem cell transplantation (HCT) and are at high risk of its failure? This question was posed by authors from King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh. They presented their findings in a poster session at this year's virtual European Society for Blood and Marrow Transplantation (EBMT 2022) congress.

Source: Hematologic Malignancies 27. 4. 2022

News How do patients perceive the treatment of ITP with romiplostim?

Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.

Source: Immune Thrombocytopenia 15. 4. 2024

News Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab

The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 4. 3. 2024